Oliver Grauer

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters

Peter Flachenecker, Tania Kümpfel, Boris Kallmann et al. · Multiple Sclerosis Journal · 2002 · 635 citations

Medicine, Neurology, Neuroimmunology +14

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors

Joannes F.M. Jacobs, Albert J. S. Idema, Kalijn F. Bol et al. · Neuro-Oncology · 2008 · 256 citations · Full text

Life Sciences, Immunology, Oncology +17

CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses <i>in vivo</i>

Oliver Grauer, Stefan Nierkens, Erik Bennink et al. · International Journal of Cancer · 2007 · 210 citations · Full text

Life Sciences, Immunology, Oncology +17